Absstract of: WO2026234380A1
The invention relates to bispecific antibodies, and particularly to antibodies that specifically bind to IL-18 and IL-13. The invention extends to compositions comprising the antibodies, including pharmaceutical compositions and kits. The invention also extends to methods of making and using the antibodies, for example in therapy and diagnosis. More specifically, the invention pertains to a bispecific antibody that targets IL-18 and IL-13, and can be used for the treatment of diseases associated with excessive or dysregulated IL-18 and IL-13 activity, including atopic dermatitis, asthma and inflammatory bowel disease (IBD).
Absstract of: WO2026234381A1
The invention relates to bispecific antibodies, and particularly to antibodies that specifically bind to IL-18 and IL-23. The invention extends to compositions comprising the antibodies, including pharmaceutical compositions and kits. The invention also extends to methods of making and using the antibodies, for example in therapy and diagnosis. More specifically, the invention pertains to a bispecific antibody that targets IL-18 and IL-23 and can be used for the treatment of diseases associated with excessive or dysregulated IL-18 and IL-23 activity, including inflammatory bowel disease and chronic inflammatory skin diseases.
Absstract of: WO2026234386A1
The invention relates to bispecific antibodies, and particularly to antibodies that specifically bind to IL-18 and TL1A. The invention extends to compositions comprising the antibodies, including pharmaceutical compositions and kits. The invention also extends to methods of making and using the antibodies, for example in therapy and diagnosis. More specifically, the invention pertains to a bispecific antibody that targets IL-18 and TL1A, and can be used for the treatment of diseases associated with excessive or dysregulated IL-18 and TL1A activity, including inflammatory bowel disease (IBD), asthma, and fibrotic diseases.
Absstract of: US20260347488A1
The invention belongs to the field of biomedicine, and particularly relates to a humanized anti-human CD132 monoclonal antibody and a use thereof. According to the invention, based on monoclonal chimeric antibodies 2D4 and 5H10 previously obtained in the laboratory, humanized transformation is performed on a target antibody, so as to screen and obtain high-affinity humanized monoclonal antibodies h2D4H4K12 and/or h5H10H6K4 targeting human CD132, so that, without attenuating antibody activities, immunogenicities of parental chimeric antibodies are reduced, thereby reducing the risk of potential immune responses to the antibodies in patients receiving the antibodies. The antibodies have promising application prospects in therapeutic drugs for prevention, neutralization or treatment of autoimmune diseases related to IL-4, IL-7, IL-9, IL-15 and/or IL-21 cytokines (such as systemic lupus erythematosus, rheumatoid arthritis, vitiligo, psoriasis, alopecia areata, inflammatory bowel disease, systemic sclerosis, graft-versus-host disease and aplastic anemia).
Absstract of: US20260351393A1
A non-contact bowel movement detection system for a dependent individual includes a patient unit, a cloud-based processing platform, and a mobile application. The patient unit is positioned in an occupied room and includes a housing with air intake apertures on a side surface and air exhaust apertures on a top surface. The housing contains a microcontroller with wireless communication, gas sensors including hydrogen, hydrogen sulfide, and volatile organic compounds, and a temperature and humidity sensor. An internal fan draws ambient air through the intake apertures, across the sensors, and out through the exhaust apertures to enhance detection. The microcontroller periodically collects sensor data and transmits it to the cloud platform. The cloud platform applies a machine-learning model to determine a bowel movement probability and generates an alert when a threshold is met. The mobile application receives and forwards the alert to a caregiver device.
Absstract of: WO2026232134A1
Provided herein are biomarkers that are useful in various aspects of treating an inflammatory bowel disease (IBD), e.g., Crohn's disease and ulcerative colitis (UC). In some aspects, the biomarkers provided herein can be used in identifying subjects that are suitable for a treatment with a bacterial composition.
Absstract of: US20260347950A1
Methods of selecting prebiotics, optionally resistant starch, optimized for an individual with inflammatory bowel disease and methods of treating individuals with the selected prebiotics are provided.
Absstract of: US20260338775A1
The present invention relates to a method for determining the presence of Mycobacterium avium paratuberculosis in a subject. The method comprises: (i) determining the level of one or more metabolites in a sample from the subject; and (ii) comparing the level of said one or more metabolites with the level of said one or more metabolites in a control sample to determine whether Mycobacterium avium paratuberculosis is present in the subject. The metabolites are selected from: 2-hydroxyglutaric acid; leukotriene B4; itaconic acid; bicyclo-prostaglandin E2; N6-acetyl-L-lysine; guanidinobutanoic acid; creatine; docosahexaenoic acid; cis-10-nonadecenoic acid; creatinine; 5-hydroxyeicosapentaenoic acid, 17-hydroxy docosahexaenoic acid, palmitoleic acid; R-3-hydroxy-octadecanoic acid; 8,11,14-eicosatrienoic acid; nonadecanoic acid; stearic acid; eicosapentaenoic acid; 16-methylheptadecanoic acid; phytanic acid; arachidonic acid; 9,10-dihydroxy-12-octadecenoic acid, 8,11,14,17-eicosatetraenoic acid; palmitic acid; pyruvic acid; and p-cresol.
Absstract of: AU2025255306A1
Provided are a new antibody and antibody fragment that specifically bind to IL-15, and a composition containing the antibody or antibody fragment. Furthermore, provided are a nucleic acid encoding the antibody or antibody fragment thereof, a host cell containing same, and the related use. In addition, provided are the therapeutic and diagnostic uses of the antibodies and antibody fragments.
Absstract of: AU2025258452A1
Provided herein are an antibody or antigen binding fragment that specifically recognizes and/or binds to an anti-interleukin 6 receptor. The antibodies or antigen binding fragments provided by the present disclosure have biological activity, FcRn affinity and antibody stability, and have prospects for clinical application.
Absstract of: WO2025185637A1
Provided are methods for determining the risk of, diagnosing, preventing, or treating Crohn's Disease (CD), ulcerative colitis (UC) and/or inflammatory bowel disease (IBD) in an individual. Some embodiments provide kits and computer program products for determining the risk of or diagnosing Crohn's Disease (CD), ulcerative colitis (UC) and/or inflammatory bowel disease (IBD) in an individual. Other example embodiments are described herein. In certain embodiments, the disclosed methods and kits are accurate, cost-effective and non-invasive.
Absstract of: KR20260151842A
본 발명은 칼프로텍틴 및 NO를 감지하는 YES 논리 게이트 포함하는 이중 AND 논리 게이트 바이오 회로에 대한 것으로, 이는 세린 재조합효소를 통해 DNA 재배열을 유도하여 형광 리포터 및 FLP 기반 메모리 모듈을 포함한다. 상기 바이오 회로를 통해 염증성 장질환(IBD)을 높은 특이도로 진단하고, 유전자 수준에서 진단 결과를 저장할 수 있다.
Absstract of: AU2025229905A1
The present invention provides an improved breath analyzer and breath test method to determine the presence of disease in humans, including but not limited to, H. pylori infection, Celiac Disease, Metabolic dysfunction-associated steatohepatitis (MAHD), Inflammatory Bowel Disease (JBD). 'm a subject's digestive tract. In certain embodiments, the present invention provides a universal breath testing platform and methods of testing for diseases of the gastrointestinal tract, the liver, the kidneys, and the lungs, along with testing for cancer, infections, and metabolic diseases.
Absstract of: WO2026217813A1
Induced pluripotent stem cells (iPSCs) were generated from patients with Crohn's disease and directed to human intestinal organoids, from which and subsequently purify the mesenchymal cell component was purified and obtained. Individual patient's iPSC-derived mesenchymal cells were used to screen for potential anti-fibrotic therapies.
Absstract of: WO2026217925A1
Provided herein are methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having inflammatory bowel disease. In particular, the disclosure relates to using assays that detect peptidoglycan recognition proteins and/or tissue inhibitor of metalloproteinase-2 in a biological sample (for example a stool sample) of the subject as diagnostic and prognostic biomarker assays in IBD.
Absstract of: WO2026215387A1
The present invention relates to a method for the diagnosis of an IgE-mediated disease based on the measurement of the amount, or relative proportion, of IgE proteoforms resulting from the proteolytic cleavage of IgE by proteases at one or more specific sites within one or both ε heavy chains.
Absstract of: US20260309721A1
The present invention relates to methods of immunoassay for detecting HNE-generated fragments of the α1 chain of type III collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. The present invention also relates to monoclonal antibodies and assay kits for use in said methods of immunoassay.
Absstract of: US20260306484A1
The invention relates to the use of a ROR inverse agonist or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for modulating RORs and/or controlling autoimmune diseases and antibody mediated rejection in a patient. The RORs mediated disease or autoimmune disease includes HIV, cancer, celiac disease, diabetes mellitus type 1, Graves' disease, inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, asthma, dermatitis, fatty liver disease, Crohn's disease, cardiovascular disease, inflammatory diseases, neurological disorder, multiple sclerosis, acute respiratory distress syndrome and arteriosclerosis.
Absstract of: US20260309591A1
A system and method for monitoring gastrointestinal health using a passive air-sampling device positioned on top of a toilet tank. The device comprises a gas sensor array, environmental sensors, and a processor configured to collect data during a user's bowel movement. Gas signatures are analyzed using machine learning to identify users and assess gut health without requiring stool handling. A proprietary health score is generated from sensor and contextual data and displayed to the user via a mobile application. The system continuously improves by associating sensor patterns with user-reported symptom classifications and retraining its algorithms to detect gastrointestinal conditions. The neural-network-enabled gas sensor produces multidimensional digital fingerprints of sampled gas compositions, enabling condition screening based on complex patterns rather than predefined biomarkers. The application includes a goal-setting chatbot using cognitive behavioral therapy methods to promote habit change. Data processing is distributed across on-device inference, edge AI, and cloud services.
Absstract of: WO2026207459A1
Methods comprising administering a therapeutically effective amount of H2S scavenger, and optionally butyrate, as described herein, to a subject who has an inflammatory gut condition, e.g., Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC), colonic Crohn's Disease (CD), pouchitis and inflammation after proctocolectomy with ileal pouch-anal anastomosis (j-pouch surgery) to treat UC, irritable bowel disease (IBD), and subjects who have those conditions who are at risk of developing colon/colorectal cancer.
Absstract of: US20260298945A1
Predicting non-responsiveness of IBD patients The present invention relates to an in vitro method for predicting the responsiveness of an IBD patient to a therapy with an intracellularly acting immunosuppressive agent of interest, wherein a sample is provided from the IBD patient at an initial period of a treatment with the immunosuppressive agent of interest, said sample comprising effector mononuclear cells, and responsiveness is predicted from the difference between a multidrug ABC transporter activity level in the effector mononuclear cells in said sample and a reference transporter activity level. The method is useful in a treatment of IBD, e.g. in monitoring the progress of the disease or in a decision on a shift from an initial treatment with an agent to another agent like csDMARD or tsDMARD.
Absstract of: US20260297673A1
0000 Blood-based genome-wide DNA methylation profiles are utilized to develop a reliable test to diagnose irritable bowel syndrome (IBS) versus inflammatory bowel disease (IBD), celiac disease and other gastrointestinal diseases that mimic IBS. These methods provide a means to rule out IBS and rule-in active IBD or celiac disease, as well as to rule-out active IBD and celiac disease, and to rule-in IBS.
Absstract of: WO2025107068A1
It is provided a method of detecting inflammatory bowel disease (IBD) in a patient comprising the step of measuring in a sample of said patient protein expression from the sample, and determining from the measured expression the presence or absence in the patient of inflammatory bowel disease. The method comprises measuring the protein expression level measured of S100-A9, neutral ceramidase, serum albumin, chymotrypsin-C, protein S100-A4, alpha-1-acid glycoprotein 1, neprilysin, lactotransferrin, immunoglobulin lambda-like polypeptide 5, immunoglobulin heavy variable 4-28, protein S100-A8, chymotrypsin-like elastase family member 3A, IgGFc-binding protein, mucin-2, antithrombin-l 11, myeloblastin, zymogen granule membrane protein 16, annexin A2, glyceraldehyde-3-phosphate dehydrogenase, chloride anion exchanger, and/or a combination thereof.
Absstract of: CN122842947A
The invention discloses an IBD patient depression risk prediction method based on artificial intelligence, and belongs to the technical field of intelligent medical auxiliary diagnosis. The method comprises the following steps: collecting multi-dimensional physiological time sequence data of an IBD patient, wherein the multi-dimensional physiological time sequence data at least comprises an intestinal inflammation marker concentration sequence, a heart rate variation sequence and a body movement acceleration sequence; performing time alignment and missing value interpolation on the multi-dimensional physiological time sequence data to obtain an equally-spaced resampling sequence set; performing phase-space reconstruction on each pair of sequences in the resampling sequence set to obtain an orbit matrix pair; calculating a cross recursion plot between each pair of orbit matrixes, and extracting a recursion rate, a longest diagonal length and a vertical recursion rate from the cross recursion plot as coupling features; coupling features from all sequence pairs are spliced into a multi-dimensional feature vector. According to the method, the nonlinear coupling relationship among the multi-modal physiological time sequence data of the IBD patient can be captured, and quantifiable depression risk grading can be realized based on coupling characteristics.
Nº publicación: CN122832968A 29/09/2026
Applicant:
SHANDONG UNIV
\u5C71\u4E1C\u5927\u5B66
Absstract of: CN122832968A
The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to a CAR-ILC2 cell, an immunotherapy method and application of the CAR-ILC2 cell. Specifically, MAdCAM-1 expressed by enteritis focus vascular endothelial cell specificity up-regulation is used as a targeting antigen, a chimeric antigen receptor is constructed, ILC2 cells are modified to obtain CAR-ILC2 cells, the biological functions of the ILC2 cells of naturally secreting Areg and other cell factors, promoting intestinal epithelium repair and relieving colitis are utilized, the specific targeting ability of a CAR structure on MAdCAM-1 is combined, and the CAR-ILC2 cells can be used for preparing the enteritis targeted CAR-MAD-1, so that the enteritis targeted CAR-MAD-1 can be used for preparing the enteritis targeted CAR-MAD-1. The CAR-ILC2 cells can be precisely targeted to an enteritis focus part, and the intestinal injury repairing and anti-inflammatory effects are exerted, so that the CAR-ILC2 cells have a good practical application value.